Results 281 to 290 of about 1,048,296 (327)

Analysis of immunogenicity and purification methods in conjugated polysaccharide vaccines: a new approach in fighting pathogenic bacteria. [PDF]

Front Immunol
Sheikhi A, Shirmohammadpour M, Mahdei Nasirmahalleh N, Mirzaei B.   +3 more
europepmc   +1 more source

Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.

Vaccine
Emary K, Bentsi-Enchill AD, Giersing BK, Gordon M, Dale H, Chirwa EB, Johnston P, MacLennan CA, Kariuki S, Excler JL, Kim JH, Kaminski RW, Wilder-Smith A, iNTS vaccine Consultation Expert Group.   +13 more
europepmc   +1 more source

Report of the Ninth Asian National Control Laboratory Network meeting in 2024, with a focus on regional harmonization of regulatory systems to prepare for cross-border transfer of plasma.

Biologicals
Choi CW, Choi Y, Maryuningsih YS, Shin JH, Chantarasomchin P, Mizukami T, Ng SW, Thi DL, Ramondrana D, Dimapilis GN, Sohn KH, Roh HS, Koh HJ, Lee W, Kim YH.   +14 more
europepmc   +1 more source

The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial.

Lancet Glob Health
Feng S, Zhang Y, Khanam F, Voysey M, Pitzer VE, Qadri F, Clemens JD, Pollard AJ, Liu X.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Meningococcal conjugate vaccines

Expert Opinion on Pharmacotherapy, 2004
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
David S. Stephens, Shanta M. Zimmer
openaire   +3 more sources